Novartis, the company that makes Bufferin, was created in 1996 by the merger of the Swiss companies Ciba-Geigy and Sandoz, and is a world leader in the research and development of products that protect and improve health and well-being.

Its core businesses are pharmaceuticals, vaccines, consumer health, generics, eye care and animal health.
Novartis derives its name from the Latin words novae artes meaning "new skills." The term reflects the company's commitment to research and development that brings innovative new products to the communities it serves.

In 2009, the Novartis Group Companies achieved net sales of USD 44.3 billion and net income of USD 10.3 billion. The Group, which invested USD 7.2 billion in research and development (R&D) employs approximately 96,700 people in 140 countries around the world, nearly a quarter of whom are based in the US. Its global headquarters are located in Basel, Switzerland, and its US headquarters are in New Jersey.